What is Mucopolysaccharidosis type VI?
Mucopolysaccharidosis type VI (MPS VI), also known as Maroteaux-Lamy syndrome, is a rare inherited metabolic disorder caused by deficiency of the enzyme arylsulfatase B (ARSB). This enzyme deficiency leads to the accumulation of complex carbohydrates called glycosaminoglycans (GAGs) in cells throughout the body, causing progressive damage to multiple organ systems. MPS VI affects approximately 1 in 250,000 to 1 in 300,000 newborns worldwide. Unlike many genetic conditions, MPS VI typically spares intellectual development, allowing individuals to maintain normal cognitive function while facing significant physical challenges.
Key statistics
| Prevalence | 1 in 250,000-300,000 births |
| Carrier frequency | Approximately 1 in 250-275 individuals |
| Age of onset | Birth to early childhood (symptoms typically emerge by age 2-6) |
| Life expectancy | Variable; 10-20 years without treatment, significantly improved with early intervention |
Symptoms
Common symptoms include: Growth retardation, joint stiffness, corneal clouding, heart valve disease, enlarged liver and spleen, distinctive facial features, hearing loss, dental problems, sleep apnea, hernias.
The clinical presentation of MPS VI varies considerably, ranging from severe forms appearing in infancy to milder variants diagnosed in adulthood. Early symptoms often include growth delays and joint stiffness, particularly affecting the hands, shoulders, and hips. Children typically develop characteristic facial features including a prominent forehead, thick lips, enlarged tongue, and coarse facial features.
Corneal clouding is nearly universal, beginning in early childhood and progressively affecting vision. Heart complications include thickening of heart valves, leading to valve regurgitation or stenosis that can cause heart failure if untreated. Respiratory issues are common due to airway narrowing, enlarged adenoids and tonsils, and chest wall deformities.
Skeletal abnormalities, collectively called dysostosis multiplex, include short stature, spinal deformities, joint contractures, and distinctive bone changes visible on X-rays. Neurological complications may include spinal cord compression due to vertebral abnormalities and hydrocephalus in severe cases, though intelligence remains normal in most individuals.
Causes and risk factors
MPS VI is caused by mutations in the ARSB gene located on chromosome 5, which provides instructions for making the enzyme arylsulfatase B. This enzyme normally breaks down specific GAGs, particularly dermatan sulfate and chondroitin sulfate, within cellular structures called lysosomes.
The condition follows an autosomal recessive inheritance pattern, meaning individuals must inherit two defective copies of the ARSB gene (one from each parent) to develop the disease. Parents who carry one mutated copy are typically healthy carriers with no symptoms.
Risk factors include having parents who are carriers of ARSB mutations, particularly in populations with higher carrier frequencies or where consanguineous marriages are common. Unlike acquired diseases, there are no environmental or lifestyle factors that influence the development of MPS VI.
Prevention
As a genetic condition, MPS VI cannot be prevented through lifestyle modifications or environmental interventions. However, genetic counseling and testing can help families understand their risk and make informed reproductive decisions.
Carrier testing is available for individuals with a family history of MPS VI or those from populations with known higher carrier frequencies. Prenatal diagnosis can be performed through chorionic villus sampling or amniocentesis to measure ARSB enzyme activity or identify genetic mutations.
Preimplantation genetic diagnosis (PGD) is an option for couples where both partners are known carriers, allowing selection of unaffected embryos during in vitro fertilization. Newborn screening for MPS VI is being implemented in some regions to enable early diagnosis and treatment initiation.
Complications
Without treatment, MPS VI leads to progressive, life-threatening complications affecting multiple organ systems. Cardiovascular complications include severe heart valve disease requiring surgical intervention and potential heart failure. Respiratory complications range from obstructive sleep apnea to restrictive lung disease due to chest wall deformities and small airways.
Skeletal complications include severe joint contractures limiting mobility, spinal cord compression requiring surgical decompression, and progressive scoliosis. Vision loss from corneal clouding may necessitate corneal transplantation. Hearing loss can be both conductive and sensorineural, potentially requiring hearing aids or surgical intervention.
Gastrointestinal complications include chronic diarrhea and malabsorption. In severe cases, hydrocephalus may develop, requiring shunt placement. The combination of these complications significantly impacts quality of life and can lead to premature death in the second or third decade of life without appropriate treatment.
Diagnosis
Diagnosis of MPS VI requires a combination of clinical assessment, biochemical testing, and genetic analysis. Initial clinical suspicion often arises from the characteristic constellation of symptoms, particularly the combination of growth delays, joint stiffness, corneal clouding, and distinctive facial features.
Biochemical diagnosis involves measuring ARSB enzyme activity in white blood cells or fibroblasts, with significantly reduced activity confirming the diagnosis. Urine GAG analysis shows elevated excretion of dermatan sulfate and chondroitin sulfate. Genetic testing identifies specific mutations in the ARSB gene and can help predict disease severity.
Imaging studies reveal characteristic skeletal abnormalities of dysostosis multiplex, including bullet-shaped vertebrae, broad ribs, and distinctive changes in the pelvis and long bones. Echocardiography assesses heart valve function, while ophthalmologic examination documents corneal clouding severity.
Additional diagnostic studies may include pulmonary function tests, hearing assessments, and neuroimaging to evaluate for spinal cord compression or hydrocephalus.
Treatment
Treatment for MPS VI has been revolutionized by enzyme replacement therapy (ERT) with galsulfase, which received approval for treating this condition. This recombinant human arylsulfatase B is administered weekly through intravenous infusion and can significantly improve walking ability, reduce liver and spleen enlargement, and enhance overall quality of life when started early.
Supportive care remains crucial and includes surgical interventions such as heart valve repair or replacement, corneal transplantation for severe vision impairment, and orthopedic procedures to address joint contractures and spinal deformities. Airway management may require adenotonsillectomy, continuous positive airway pressure (CPAP) for sleep apnea, or tracheostomy in severe cases.
Physical and occupational therapy help maintain joint mobility and functional independence. Regular cardiology, ophthalmology, and pulmonology monitoring is essential for early intervention. Pain management strategies may include analgesics and anti-inflammatory medications.
Hematopoietic stem cell transplantation (HSCT) has been performed in select cases, particularly for patients diagnosed early in life, though the risks and benefits must be carefully considered for each individual.
Prognosis
The prognosis for MPS VI has improved significantly with the advent of enzyme replacement therapy and comprehensive supportive care. Without treatment, individuals with severe forms typically survive into their teens or early twenties, while those with milder variants may live longer but experience progressive disability.
With early initiation of ERT, many symptoms can be stabilized or improved, particularly joint mobility, exercise tolerance, and organomegaly. However, ERT has limited effects on existing skeletal abnormalities and does not cross the blood-brain barrier to address neurological complications.
Long-term outcomes depend heavily on the timing of diagnosis and treatment initiation, disease severity, and access to comprehensive care. Individuals diagnosed and treated early often experience better functional outcomes and quality of life. Normal intelligence is preserved in most cases, allowing for educational and vocational achievement with appropriate support.
Quality of life
Living with MPS VI requires adaptation and comprehensive support, but many individuals can lead fulfilling lives with appropriate management. Regular physical therapy is crucial for maintaining joint mobility and preventing contractures. Low-impact exercises such as swimming can help maintain cardiovascular fitness while being gentle on joints.
Educational accommodations may be needed for vision or hearing impairments, though intellectual abilities are typically preserved. Vocational rehabilitation can help individuals find suitable employment that accommodates physical limitations. Psychological support is important for coping with the challenges of a chronic condition and maintaining mental health.
Dietary considerations may include managing swallowing difficulties and ensuring adequate nutrition despite gastrointestinal symptoms. Sleep quality can be improved through treatment of sleep apnea and appropriate sleep positioning. Social connections and peer support through patient organizations provide valuable emotional support and practical advice.
Adaptive equipment and home modifications can enhance independence in daily activities. Regular respite care can provide relief for caregivers and families managing the intensive care requirements.
Pregnancy and fertility
Fertility is generally not directly affected by MPS VI, though severe skeletal deformities may complicate pregnancy and delivery. Women with MPS VI considering pregnancy require careful preconceptional counseling regarding the 25% risk of having an affected child if their partner is also a carrier.
Pregnancy management requires a multidisciplinary approach, with particular attention to cardiovascular and respiratory status. Heart valve disease may worsen during pregnancy due to increased blood volume and cardiac output. Airway management during labor and delivery requires careful planning due to potential difficult intubation.
The safety of galsulfase during pregnancy has not been definitively established, though it may be continued based on individual risk-benefit assessment. Prenatal diagnosis should be offered to all at-risk pregnancies. Cesarean section may be necessary due to skeletal abnormalities affecting pelvic structure.
Genetic counseling is essential for family planning decisions and understanding reproductive options including prenatal diagnosis and preimplantation genetic diagnosis.
Children
Early diagnosis and treatment initiation in childhood are crucial for optimal outcomes in MPS VI. Pediatric management focuses on growth monitoring, developmental assessment, and early intervention services. Regular multidisciplinary clinic visits coordinate care across multiple specialties.
Educational planning should address potential vision and hearing impairments while capitalizing on preserved cognitive abilities. Physical therapy and occupational therapy help maintain function and prevent complications. Social and emotional support helps children cope with differences and build self-esteem.
Transition planning to adult care should begin in adolescence, ensuring continuity of specialized care. Immunizations may require special consideration due to potential increased infection risk. Growth hormone therapy is sometimes considered for severe growth retardation, though evidence for efficacy is limited.
When to see a doctor
Seek immediate medical attention for signs of heart failure including difficulty breathing, chest pain, or fainting, as these may indicate worsening valve disease. Neurological symptoms such as weakness, numbness, or loss of bladder control could signal spinal cord compression requiring urgent evaluation.
Routine medical care should include regular monitoring with a metabolic specialist familiar with MPS VI. New or worsening joint pain, vision changes, or hearing problems warrant prompt evaluation. Recurrent respiratory infections or sleep disturbances may indicate airway complications requiring intervention.
Emergency medical care is needed for severe breathing difficulties, which could indicate airway obstruction or respiratory failure. Persistent fever or signs of infection should be evaluated promptly, as individuals with MPS VI may be at increased risk for complications.
Regional context
Limited data exists regarding the prevalence of MPS VI specifically in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean countries. However, these regions’ genetic diversity and population history may influence carrier frequencies and mutation patterns.
Consanguineous marriages, more common in some parts of these regions, may increase the risk of autosomal recessive conditions like MPS VI. Access to specialized diagnostic testing and treatment may be limited in some areas, highlighting the importance of telemedicine consultations and regional medical collaborations.
We invite healthcare providers and researchers from the Caucasus and Eastern Mediterranean regions to contribute data and insights about MPS VI prevalence, carrier frequencies, and management approaches in their populations to the Global Medical Journal.
Research and clinical trials
Current research focuses on improving enzyme replacement therapy delivery, including novel formulations that might better reach affected tissues. Gene therapy approaches are being investigated, with several early-stage clinical trials examining the safety and efficacy of delivering functional ARSB genes to patients.
Substrate reduction therapy, which aims to decrease GAG production rather than increase breakdown, is being explored as a complementary approach. Novel delivery methods for crossing the blood-brain barrier to address neurological complications are under investigation.
Research into biomarkers for monitoring disease progression and treatment response continues to advance. Patients interested in clinical trials can search for opportunities at ClinicalTrials.gov using the terms “mucopolysaccharidosis VI” or “Maroteaux-Lamy syndrome.”
Long-term outcome studies are providing valuable data on the effectiveness of early treatment and optimal management strategies. Newborn screening implementation studies are evaluating the benefits of early diagnosis and intervention.
Frequently asked questions
Is intelligence affected in MPS VI?
No, intelligence is typically preserved in MPS VI, distinguishing it from some other MPS types. However, vision and hearing problems may affect learning and require appropriate accommodations.
How effective is enzyme replacement therapy?
Enzyme replacement therapy with galsulfase can significantly improve walking ability, reduce organ enlargement, and enhance quality of life, especially when started early. However, it cannot reverse existing skeletal abnormalities or cross the blood-brain barrier.
Can people with MPS VI have children?
Yes, fertility is generally not affected, though pregnancy requires careful medical management. There is a 25% risk of having an affected child if both parents are carriers.
What is the life expectancy with treatment?
Life expectancy has improved significantly with modern treatments, though it varies based on disease severity and treatment timing. Many individuals now live into adulthood with appropriate care.
Are there any dietary restrictions?
There are no specific dietary restrictions for MPS VI, though some individuals may need modified textures due to swallowing difficulties or dental problems.
Support and resources
International Organizations:
– National MPS Society: mpssociety.org
– International MPS Network: mpssociety.org
– EURORDIS (European Rare Disease Organisation): eurordis.org
– National Organization for Rare Disorders (NORD): rarediseases.org
– Orphanet: orpha.net
Research and Clinical Resources:
– ClinicalTrials.gov: Search “mucopolysaccharidosis VI”
– Genetic and Rare Diseases Information Center: rarediseases.info.nih.gov
Related conditions
– Mucopolysaccharidosis type I
– Mucopolysaccharidosis type II
– Mucopolysaccharidosis type III
– Mucopolysaccharidosis type IV
– Multiple sulfatase deficiency
Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.
Cite this page
GMJ News Desk. “Mucopolysaccharidosis type VI.” GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/condition/mucopolysaccharidosis-type-vi/
Licensed under CC BY 4.0. Free to share with attribution to GMJ News.Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.
Was this article helpful?